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Abstract
Background: Women bear a disproportionate burden of HIV throughout the world prompting extensive research
into HIV prevention products for women which has met with varied success. With an aim of informing future policy
and programming, this review examines the barriers and motivations to the uptake and use of female initiated products
in sub-Saharan countries.
Methods: We conducted a systematic review as an adapted meta-ethnography of qualitative data focused on actual use
of products. After deduplication, 10,581 and 3861 papers in the first and second round respectively were screened.
Following the PRISMA guidance, 22 papers were selected and synthesized using Malpass’s definitions of first, second,
and third order constructs. First order constructs, consisting of participant data published in the selected papers,
were extracted and categorised by second and third order constructs for analysis. A weight of evidence review was
conducted to compare and assess quality across the papers.
Results: The 22 papers selected span 11 studies in 13 countries. We derived 23 s order constructs that were translated
into seven overarching third order constructs: Sexual Satisfaction, Trust, Empowerment and Control, Personal Well-being,
Product use in the social-cultural environment, Practical Considerations, Risk Reduction, and Perceptions of Efficacy.
Relationships and trust were seen to be as or more important for product use as efficacy. These constructs reveal an
inherent inter-relationality where decision making around HIV prevention uptake and use cannot be binary or
mono-faceted, but rather conducted on multiple levels. We developed a framework illustrating the central
and proximal natures of constructs as they relate to the decision-making process surrounding the use of
prevention products.
Conclusions: Health systems, structural, and individual level HIV prevention interventions for women should
adopt a holistic approach. Interventions should attend to the ways in which HIV prevention products can serve to reduce
the likelihood of HIV transmission, as well as help to protect partnerships, enhance sexual pleasure, and take into account
woman’s roles in the social environment. Stigma, as well as sexuality, is likely to continue to influence product
uptake and use and should be prominently taken into account in large-scale interventions.
Trial registration: Not applicable.
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Background
Women bear a disproportionate burden of HIV infection
across the world, and in particular in sub-Saharan Africa
[1]. Until recently, the only readily available HIV prevention
options for women have been male condoms. Female
condoms were at one time a promising new option,
however lack of support from international agencies and
funders translated into challenges in delivery and access
[2–4]. This meant that male condoms have remained the
dominant form of HIV prevention for decades. Additionally,
post-exposure prophylaxis (PEP), while proven to be effica-
cious in preventing HIV acquisition [5, 6], has generally only
been available for health workers and rape victims [7, 8].
Advances in HIV prevention research have yielded a
new approach: pre-exposure prophylaxis (PrEP). PrEP is
the use of antiretroviral drugs taken orally by people
who do not have HIV to prevent acquisition of the virus.
A recent systematic review of oral PrEP including 18
studies found that “PrEP use with greater than 70%
adherence demonstrated the highest PrEP effectiveness
(RR = 0.30, 95% CI: 0.21-0.45, p < 0.001) compared to
placebo”, confirming that oral PrEP will prevent HIV
with high rates of efficacy when taken consistently [9].
This review did not include one study completed with
people who inject drugs [10], which found a moderate
but significant level of efficacy, nor did it include two
microbicide gel1 studies (CAPRISA004 and FACTS001),
the results of which together did not prove product effi-
cacy [11, 12]. The non-significant levels of efficacy in the
two microbicide trials, as well as the similar results of
the VOICE (comparing oral PrEP and microbicide gel)
and FEMPrEP (oral PrEP only) trials were either partially
or largely due to poor adherence [13, 14], opening up
questions around the ability to take oral PrEP effectively.
Qualitative research conducted as part of these clinical
trials has explored reasons for poor adherence. Reasons
range from apathy towards the research itself, dislike of
product side effects, lack of privacy in which to use the
products, low risk perception, and access to better
healthcare offered in studies as primary motivation for
study participation [15, 16]. The insights arising from
these studies, conducted primarily in sub-Saharan Africa
and India, combined with lessons learned from past
research of other HIV prevention products will provide
the field with further understanding of why and how
women take up and use HIV prevention products, which
can inform better implementation.
This is a systematic literature review conducted in the
form of a meta-ethnography to synthesize qualitative find-
ings from research on the practical use of HIV prevention
products among populations of women across sub-
Saharan Africa. Broadly, our aim is to inform future policy
and programming for HIV prevention products for women
going forward, by drawing on the wealth of information
already published from the research conducted in
sub-Saharan Africa. As such, the primary objective of this
review is to identify and understand the motivations and
barriers affecting uptake and use of female-initiated, pri-
mary biomedical HIV prevention products for women in
sub-Saharan Africa.
Methods
We conducted a systematic review using a meta-
ethnographic approach following the principles set out by
Noblit and Hare [17]. This approach allows for a
sophisticated and robust manner of synthesis as compared
to a typical literature review of qualitative data, and
focuses on interpretation through analysis of constructs
rather than summarization of themes [18]. For this review,
we conducted an adapted meta-ethnography as defined
more recently by several researchers [19–21], which
allows for qualitative data collected through a variety of
methods, such as interviews and focus groups, as well as
ethnographies, to be combined and interpreted. Qualitative
data are best placed to answer the questions around how
and why products are utilised effectively, rather than meas-
uring only their uptake or adherence. Throughout this
process, we also employed the guidance set forth by the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) Statement and the Centre for
Reviews and Dissemination (CRD) [22, 23]. The protocol
for this review has been published and the methods
described in more detail [24].
This review was not registered on PROSPERO since
reviews of qualitative evidence are not currently included
on the PROSPERO database. Additionally, the original
protocol articulated “female-initiated HIV prevention
technologies” in the title, however we chose to change
technologies to products in the final paper.
Search strategy and inclusion criteria
We searched seven databases: Africa-wide Info,
CINAHL, Embase, Global Health, Medline, Psychinfo,
and Web of Science. The search strategy comprised four
primary concepts: HIV prevention; uptake and use;
qualitative research; and sub-Saharan Africa, which were
first confirmed through iterative pilot searching in
Medline, and then adapted for the other databases. The
first set of searches was conducted in July of 2013, and
then again in July of 2015.
Papers were included in the review if they met the
following criteria: women aged 18 and above; data focused
on female-initiated products (oral PrEP, microbicide gel,
PEP, female condom, vaginal ring, and diaphragms); in-
cluded narrative on motivations and/or barriers to uptake
and use of products; qualitative research; located in sub-
Saharan Africa; and, research conducted from 2003 or
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later. Note that female-initiated product refers to any HIV
prevention product that can be initiated and used exclu-
sively by women without requiring the involvement or
permission of a partner.
Actual experience of product use was central to this
review, rather than hypothetical acceptability studies (e.g.
where study participants did not actually have access to
products). Since few studies have been published in ‘real-
world’ programme settings, we also included data from
across research settings, both randomized control trial and
implementation. While incentives to participate in research
could be quite different to clinic attendance, in this review
we hypothesized that experiences of actual product use
should be similar regardless of initial motivation.
Additionally, we have included women’s perspectives on
use of the diaphragm and vaginal microbicide gels, despite
the limited efficacy of these products to prevent HIV. At
the time of those studies, efficacy was unknown, and im-
portantly, women’s experiences and perceptions of use ex-
tend beyond efficacy. The interest of this review is to
examine the elements that would make a product feasible
and relevant for a woman to use it, and what those salient
elements are across products.
We did not limit our search by language, and we allowed
for grey literature to be included, however none was identi-
fied through our searches or through consultation with rele-
vant subject matter experts. Studies were excluded if they
focused only on hypothetical use of products or represented
perspectives from the male point of view, HIV-positive
women only, or secondary prevention products (e.g.
Prevention of Mother to Child Transmission).
Screening and selection process
All 25,861 references identified through searching were
uploaded into the reference software manager Mendeley.
After de-duplication, two reviewers screened all 10,580
papers by title and abstract according to the inclusion and
exclusion criteria. Any discrepancies between reviewers
were discussed and mediated by a third researcher. The
papers were identified first by title and then by abstract,
and were then reviewed in duplicate by three reviewers.
There were several cases of papers published from the
same study, however we determined no overlap of data
therefore these papers were all included. The 39 papers
identified for possibility for inclusion were discussed by
the three primary reviewers during which some were elim-
inated mainly due to inability to isolate female-centred
data from male, or due to the research being conducted
before 2003. Finally, 22 papers were selected for analysis.
This process is illustrated in Fig. 1.
Analysis and synthesis
Data were extracted from the papers by two reviewers,
then sorted by themes and incorporated into a construct
worksheet. To generate the concepts for our constructs,
we employed Malpass’s definition of the first, second,
and third order constructs [25] used previously by
authors of other similar reviews [19, 20]. First order
constructs consist of participant data published in the
selected papers, and were extracted and categorised by
second and third order constructs for analysis. Second
order constructs consist of author perspectives of their
manuscript data extracted from the papers, and third
order constructs are thematic categories developed
through our analysis. In this regard, our construct work-
sheet comprised three meta-ethnographic layers: the
perspective of the participants, the perspective of the
paper authors, and the perspectives of the researchers
conducting this review. We then used the process of
concept translation, as described by Musheke et al. [20],
to arrive at our synthesized third order constructs.
Weight of evidence review
We employed a weight of evidence (WoE) review to
assess the relative strength of the papers included in the
review. A WoE review, as defined by Gough et al. [26], is a
process by which standard elements of research are identi-
fied in each paper included in the review, and then
assessed in comparison with one another to judge the
overall strength or quality of the papers [26]. The results
of our WoE are listed in Table 1. This process uses a sys-
tematic approach similar to the GRADE process used by
the World Health Organization (WHO) in assessing the
quality of quantitative studies included in systematic re-
views in support of guidelines. Each paper was assessed in
terms of relevance (how directly the paper answered the
aim of the review), appropriateness of study design, and
Fig. 1 PRISMA chart of review process
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soundness (which equates to the inclusion criteria for this
review).
Results
The 22 papers included in the review represent 11 studies
(including ancillary research as part of larger studies)
across 13 countries in sub-Saharan Africa, as shown in
Fig. 2. Since the review covers studies conducted between
2003 and 2015, more papers describe experiences using
products such as diaphragms and microbicide gels, as
compared to more recent products such as oral PrEP for
which few papers have yet been published.
We derived 23 s order constructs that we translated into
seven overarching third order constructs, mapped in
Table 2. The results presented here are organized by third
order construct labels. The findings are organised in this
way to best illustrate and organise the fluid and inter-
relational nature of the themes, which are illustrated in
Fig. 3. This is instead of a more binary presentation which
has been characteristic of other such reviews [19, 20]. It is
also important to note that while this review offers a
synthesis of the findings and an overview of the primary
themes present in this diverse literature, it was not pos-
sible to capture every nuance in all of the selected papers.
Weight of evidence review
The WoE review found a relatively high level of quality
across the body of evidence included in this adapted
meta-ethnography. No one category scored lower than
medium. Rather we found many medium-high and high
ratings. Some papers came from ancillary or imbedded
trial research which may not be considered ‘real-world’,
Fig. 2 Map indicating HIV prevention products
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and many did not explicitly focus on answering the over-
all aim articulated in this review. However, these papers
were still included because they contained data directly
responding to the review aim. All of the studies were
conducted with strong, clear methodologies which led
us to give the evidence overall a high rating.
Meta-ethnography
Sexual satisfaction
Constructs of “Sexual Satisfaction” arose in thirteen of the
papers we reviewed [27–39]. These second-order
constructs included: 1) general sexual satisfaction; 2) sex-
ual performance and play; 3) implications of enhanced sat-
isfaction; and 4) effects of vaginal lubrication and
traditional vaginal practices. Particularly strong positive
feelings were voiced in relation to vaginal microbicide gels
[27, 28, 32], as a result of the “heat”, or kusisha in isiZulu,
created through use [27]. This also occurred in relation to
diaphragms where many women reported increased
vaginal tightness [35], or enhanced stimulation when a
partner’s penis made contact with the vaginal ring [33]. At
the same time, women also reported negative reactions
from some male partners who found the ring to be
obstructive during sex [34].
Particularly striking in its primacy was discussion of
how product use could form part of sexual performance
and play between couples. Several papers describe how
the use of microbicide gels and diaphragms was inte-
grated into sexual foreplay, such as the product insertion
performed by the male partner [29, 37]. Vaginal microbi-
cide use was also associated with increased libido among
some women [32, 37] and viewed as a means of over-
coming sexual problems, particularly in limiting prema-
ture ejaculation by male partners [32, 36]. A perception
that the microbicide gel could lead to tightening of the
vagina meant that, as described in two papers, male
partners would actively request their female partners to
use the product to improve the sexual sensation [27, 37].
In a similar vein, the potential for product use was often
seen as facilitating discussion and greater sexual intimacy
between partners. Sexual pleasure itself had positive im-
pacts on relationships, improving the performance and
play among couples, but also improving the security of
the relationship for some women when their husbands
stopped seeing other women as a result of improved
sexual encounters within the primary relationship [32].
Lubrication played a key role in shaping women’s per-
ceptions of microbicide gel use with the majority of
papers reporting a positive impact that helped to make
sex feel more smooth or comfortable [27–29, 31, 37, 38].
Inserting the vaginal microbicide gel mirrored the use of
other substances inserted into the vagina to create a
pleasing environment for both themselves and their male
partner [32].
There are others who insert traditional medicines for
her to be enjoyable (during sex) . . . I used to love
things that are inserted that make you enjoyable. . . .
Fig. 3 Conceptual framework of third order constructs
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Now that I am old I don’t have that time of going to
buy such things. I get help from the gel. [32]
The multiple dimensions of Trust
We found “Trust” to be a particularly strong, complex,
and crosscutting construct, either positively or negatively
influencing product uptake and use. From various
perspectives, trust was either built up or broken down
by interactions with partners in relation to product use.
Three second-order constructs emerged under this
theme including: 1) trust in one’s partner; 2) implications
of product use for development and maintenance of
trust; and 3) communication and enabling environments
for trust building. These constructs were identified in 16
of the papers [15, 27–38, 40–43].
Women’s lack of trust in their partners was a strong
motivator for use of PrEP, female condoms, microbicide
gel, and gel with diaphragm [15, 29, 30, 35]. Product use
helped ease the fear of possible infections a man might
bring home with him, HIV or otherwise, especially when
it was difficult to insist upon the use of male condoms
within the context of a regular partnership [29, 30, 35].
Product use also had direct implications for the
development and/or maintenance of trust within the
couple. In several instances, women reported that
bringing an HIV prevention product into the home was
negatively seen by partners who felt it implied infidelity
on their part or could encourage the woman’s promiscu-
ity, thereby impacting their ability to use the products
[15, 34].
Conversely, for many couples, the microbicide gel did
not convey the same level of mistrust that the condom
had, making use easier to negotiate [37, 38]. Communi-
cation improved product use, and product use in turn
could improve sexual and relationship communication,
allowing for new dialogues and trust around sex and in-
timacy. Disclosure of product use, or lack thereof, also
had the potential to influence a woman’s standing in her
home and her relationship, where use could result in
violence or dissolution of the relationship, or help to
improve sexual satisfaction and dynamics within a
couple [28, 32, 38, 41, 43].
Partner support of product use was also a critical fac-
tor. Some partners plainly refused to use any prevention
products citing mood, general disapproval, or dislike of
added wetness from microbicide gel use [15, 28, 30].
However, in many instances, men could also be support-
ive and feel they were protected by the product, as well
as become involved in supporting their female partner in
use, such as providing transport to clinic appointments
[28, 35, 42, 43].
Finally, there was an aspect of trust in the product it-
self, either negative or positive. Negative perceptions
often manifested from male partner’s disapproval and
mistrust in outsiders having influence on sexual relation-
ships or in the efficacy of the product. On the other
hand, some couples found that a new product with
greater efficacy could actually improve trust and feelings
of safety that would motivate use, particularly when they
had previously found effective condom use problematic.
I like using the diaphragm a lot. My partner likes
condoms, but he says they are weak. I also think they
are weak [...] [Condoms] burst just like D said. It
burst while we were busy [having sex]...So I
sometimes use [the condom], but I trust the
diaphragm more. [35]
Empowerment and control
The interrelated constructs of “Empowerment and
Control” were central to women’s narratives about how
they perceived and used HIV prevention products. Two
second-order constructs were identified under this theme:
1) self-esteem and personal agency; and 2) power position-
ing. These constructs emerged from 14 of the review
papers [15, 28–31, 33–37, 40, 41, 44].
Some women expressed how products, in particular
microbicide gel, vaginal ring, and diaphragm, gave them a
sense of ownership and agency over preventing HIV, but
also their own bodies and health [33–35]. They were able
to make the decision to use a product, without a man’s
consent or involvement. This was especially valuable when
women felt that their partners would not necessarily agree
or were untrustworthy. Participants suggested that women
were responsible for their own health, as this quote notes
in relation to the female condom:
Men cannot be trusted to act in our best interests. He
can wear the condom at the start of the act and then
remove it later or he will just tear it. … So we have to
take care of ourselves by using condoms. [40]
In less common contexts, product use can also affect
agency, as described in one paper about PEP use within
the context of post-rape care. In this paper, successful
PEP use after cases of sexual assault was directly related
to how the rape was perceived and how the use of PEP
affected the victim on an emotional level [44]. Several
women reported that the use of PEP reminded them of
the rape or made them feel like they were HIV positive,
leading to negative associations with the product and
demotivated use.
In direct contrast to the generally improved self-
agency from product use is the construct of power
positioning which emerged as a barrier to product
uptake and use. A key concern in this regard was a fear
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of violence should male partners’ discover covert use of
the product.
‘I was scared of the conflict it would cause’; ‘if he finds
out he is going to be angry’; ‘I had seen that he didn’t
like the gel and I thought if I told him he would fight
with me’; ‘I think he will fight with me for using the gel
with him in secret...’ (multiple respondents) [36]
Women had conflicting feelings about product use.
Some felt product use could improve their ability to
make choices and negotiate protection, however, this
could also pose a threat to men’s authority and poten-
tially destabilize the relationship [43].
Personal well-being
“Personal Well-being” arose as an important construct in
how women used and engaged with products. We identi-
fied three distinct constructs comprising this theme: 1)
product use promoted health and well-being; 2) attributes
of product use indicated the power of medication and
good health; and 3) quality of care was a motivator for en-
gaging in services and product use. These constructs
emerged to varying degrees in five of the review papers
[15, 32, 37, 39, 42].
Two of the papers [32, 37] explored how a microbicide
gel gave women a sense of well-being, solved multiple
health issues, and prevented other diseases or infections.
Indeed the power of the prevention product was seen to
have the ability to promote fertility and vaginal
cleanliness, clean the blood, and cure ailments [32].
As a result of continuous use, my pores are now open.
My body is no longer stiff and I don’t get tired any
more. I am not unsure about my health anymore.
Since I started using the gel, I am always energetic
like somebody who is using drugs. It has even opened
the veins to my kidneys. [37]
Another paper found that the experience of side
effects from ARV-based prevention products encouraged
perceptions of the power of the ARVs working in the
body to protect the user [15, 39].
[T]he tablets are also working because they have some
reaction on us like some of us have headaches and
become nauseous and stuff like that, so you would
believe that means that these tablets have a certain
possibility of reducing the risk of contracting HIV, you
know. [15]
Interaction with a health service, whether within a trial
or actual clinic setting, driven by product use promoted
an additional sense of personal well-being in which
women could actively look after their own health and be
seen by others as ‘healthy’ [15]. Knowledge of one’s HIV
status with regular check-ups could promote a negative
status, leading to continued product use [42].
Additionally, the quality of care during clinic attend-
ance was directly related to motivation for use in two of
the papers [15, 42]. Women noted the importance of
staff demonstrating their concern and care for their
study participants or clinic clients through educational
or one-on-one counselling sessions, in contrast to previ-
ous experiences in government public health clinics
where staff were often quick to dismiss interests in new
products and/or the feelings of their patients [42].
Product use in the social-cultural environment
The construct of “Product use in the social-cultural
environment” incorporates 4 s-order constructs which,
combined, represent a significant and sizeable compo-
nent of the published evidence on the uptake and use of
female controlled HIV prevention products [15, 27, 31,
34, 35, 37–39, 42, 43, 45, 46]. The four constructs in-
clude: 1) perceived implications of use; 2) dominant,
setting-specific social construction of medication and
product use; 3) conflation of ARVs for prevention and
for treatment; and 4) interaction of products with nor-
mative vaginal practices and beliefs. Cutting across these
constructs is the notion of how women use products
within the social-cultural environment and interactions
which point to their need or desire to protect their
‘social well-being’, including their observation of social
norms and values.
Many women were concerned that use of vaginal
microbicides, the diaphragm, or oral PrEP might sug-
gest to others that they are either promiscuous or
identified them as a sex worker [27, 34]. Clinic at-
tendance and use of an ARV based technology also
caused confusion for the family and friends of some
female participants who struggled to distinguish be-
tween ARVs for treatment and for prevention [15, 42,
43]. The use of ARVs has become synonymous with
HIV infection and, in some instances, sickness [39]
and those using ARV-based prevention products were
considered to be ill. As such, the social construction
of medication and product use encapsulates particular
beliefs regarding use of medications. Therefore, a
woman’s own view of how she sees herself, and how
she is seen by others, may be threatened by the use
of a technology such as PrEP coming in the form of
a tablet [42].
Like my family, I explained that I am attending a
[PrEP] study but they don’t [believe] that I am
attending a study, they just thinking I am HIV
positive and I am hiding it. [15]
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The impact of beliefs on uptake and use of new prod-
ucts also extend beyond those that relate to HIV stigma.
Culturally appropriate or common hygiene practices as
they relate to use of prevention products are the focus of
several papers within this review [28, 37, 45, 46] and au-
thors highlight the ways in which cleansing practices, in
particular, are an important dimension of the social self.
Hygiene practices, such as using cleansing products,
were reported both as a barrier and an enabler to the ef-
fective use and acceptability of vaginal microbicides.
Some women found vaginal microbicides highly accept-
able given the existing cultural norms around intravagi-
nal insertions for cleansing and preparation for sex [28,
32]. Partner and social preferences for “dry sex” moti-
vated microbicide use which was seen to have cleansing
effects on the vagina, translating into a reduction of STIs
and foul-odours previously caused by traditional vaginal
cleansing products [37]. Interestingly, at least in the
South African context, preferences for dry sex seem to
actually refer to cleanliness or tightness rather than the
desire for a dry vaginal environment, as presented by
Stadler and Saethre [37].
The perception and extent of engagement with a bio-
medical product was also influenced by who was deliver-
ing the product and whether they were seen as part of
the community. Four studies [15, 31, 32, 47] cite con-
cerns relating to the fact that vaginal microbicides, PrEP
or the diaphragm were delivered by muzungu (white
people in Swahili) or people from the northern
hemisphere, and a generic mistrust of foreign medica-
tions not common in the local setting.
So I sometimes think what if what my friends are
saying is true, as they say ‘what if they are infecting
you with AIDS using that gel? [15]
In several instances it was male partner mistrust of
‘outsiders’ in their social setting that stood as a
significant barrier to uptake and use of the product as
they sought to prevent their female partners from
engaging in use [43].
Efficacy and risk reduction
Constructs of perceived and actual efficacy of prevention
products, or the potential for risk reduction, were a
significant feature of nine papers [28–30, 34, 37, 40, 41,
45] and an implicit dimension of three [31, 32, 39].
Three constructs identified among these papers were 1)
efficacy for HIV prevention as a central concern; 2)
other (non-HIV) protective effects; and 3) perceptions
around combination prevention.
The fear of infection was a dominant feature in partici-
pants’ narratives [28, 31] as was the hope that new
products may succeed in stemming the epidemic where
condoms have been insufficient [37]. In several studies,
women said that sex was more enjoyable when they felt
protected from HIV, as described in Guest et al.:
It is the diaphragm and gel that made us enjoy sex
more because there is no virus that goes inside me or
penetrates me. I don't know what he is doing in my
absence, and he doesn't know what I am doing in his
absence so we are safe when we are using the
diaphragm. [29]
Female participants were comforted by the additional
protection that new prevention products offered. While
they may maintain a desire to utilise male condoms for
many sexual encounters (e.g. to prevent pregnancy or
other STIs), it was felt that the diaphragm [34, 35] or
vaginal microbicides [29] could provide an additional
layer of protection from acquiring HIV.
I feel free when the diaphragm inside me in this 6
hours I do simply know that even if it has happened
that a condom burst, no HIV will be passed on to me.
It will go back. [35]
The preference for use of more than one product at a
time affording multiple layers of protection was not
uniform. Kacanek et al. (2010) highlight the reluctance of
women in their study to use both the diaphragm and
condoms simultaneously. However, women did
acknowledge that this was partly born from a desire to
understand the effectiveness of the diaphragm as a pre-
ventative HIV transmission method in isolation.
For female condoms and the diaphragm, women
articulated their belief, and feelings of comfort, that
these methods could also protect them from other STIs
and unwanted pregnancy [29, 34, 40, 41, 45]. The female
condom was particularly favoured by women who had
experienced problems with hormonal contraceptive
methods [40].
Practical considerations
Four second-order constructs emerged within the third
order construct of “Practical Considerations”. These
included: 1) accessing and storing products, 2) product
attributes and acceptability, 3) ability to effectively take
or use the product, and 4) issues relating directly to
health services. These constructs were identified in 17 of
the papers [15, 28–30, 32–35, 37, 39, 40, 42, 44–47].
While all of the studies included in this review report
data on actual use of products in contexts where the
products were provided for research purposes, either in
trials or clinic settings, issues around access to the
products still arose. This was directly related to women’s
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ability to get to the clinic for refills in between scheduled
visits. In some cases women just waited for the their
next appointment rather than making an extra trip, or
were away from home due to family obligations [28, 42].
Storing the products could also pose problems in
settings where there is little privacy in the home and
women feared accidental discovery and potentially nega-
tive reactions from household members or partners [15,
32]. Some women used the discovery of a product as a
means to establish health status and pride around use:
At first I was putting [the tablets] inside my bag and
then I took them out of it and put them inside my
wardrobe but then one of my friends opened my
wardrobe. Because she saw that I was taking the
tablets and she didn’t understand why I was taking
the tablets even my partner didn’t understand why I
was taking the tablets. So I put the tablets in open
field so that they could understand that I was taking
the tablets for the study and it’s not that I was sick or
anything like that. [15]
Attributes of the products themselves could directly
influence the ability to use them. With regard to the
diaphragm, users found that it could be problematic to
insert or remove it without privacy or clean facilities in
which to wash themselves and the product. Some
women found it painful at first to use, while others
appreciated the small size and that it was inconspicuous
enough to fit in a handbag or in a pocket [34, 35]. The
long-acting attribute of the vaginal ring contributed to a
feeling of flexibility when sex occurred, as well as con-
stant protection in case of rape [15].
Vaginal lubrication practices also arose under this third
order construct from the practical perspective. After using
microbicide gel, women articulated that the use of trad-
itional lubricants was less preferred owing to their ability
to cause foul-smelling odours, whereas the microbicide
gel or the female condom had built-in, clean lubrication
which was a strong motivator for use [28]. This built-in
lubrication would also prevent pain and tearing of con-
doms or vaginal tissues, as well as dryness, which can
occur during longer sexual encounters and as such was
preferable to male condoms [29, 32, 37]. The vaginal ring
could bring added pleasure to sex as well where the ring
itself would add stimulation to the male partner [40].
Other papers presented discussions of traditional or
conventional vaginal practices and how they might affect
the practical and effective use of products [37, 45, 46].
Women spoke of the “dirt” (or pollution resulting from
perceived accumulation of semen, menstrual blood, and
lubricants), either their partner’s or their own, which could
get trapped in their vaginas after sex because of product
use [37, 46]. However, the rinsing of a vaginal microbicide
gel or diaphragm within an hour after vaginal intercourse
could significantly negate its effectiveness. This issue was
amplified for female sex workers who felt a need to
cleanse their vagina between clients [45, 46]. Interestingly,
some women felt that using the newer products actually
made them feel cleaner, thus reducing cleansing practices
and motivating use.
Side effects, whether real or perceived, were a critical
influence on continued use of a product. Women stated
they would use products providing there were no visible
side effects which could alert friends, family, or partners
to their use and potentially stigmatize them as being HIV
positive [15]. Women expressed fear of using products
due to potential or experienced side effects [15, 33, 39],
while others were able to quickly overcome the side effects
and felt happy to use the product [28]. Lack of side effects
as experienced with the female condom was a big motiv-
ator for use, especially for those women who had experi-
enced them with other products.
An additional practical consideration centres on the
consciousness required for consistent and correct pill
taking, in particular related to oral PrEP. Some women
had difficulty remembering to use the product, such as in
the case of oral PrEP, when they were intoxicated, “feeling
bored or lazy, on the go”, or just not used to having to
take a pill every day [15, 28].
Finally, issues with health services, even in trial settings,
were also factors influencing product use. Waiting times
at the clinic would cause women not to attend and pick
up their products, as did availability of and ability to get
transport, and family, community, or work obligations
which disrupted clinic attendance [42].
Discussion
The analysis and synthesis of the data included in this
review reveal nuanced personal, relational, social and
cultural factors that women perceive and attempt to
manage as they consider the uptake and use of biomed-
ical HIV prevention products. The factors are far from
binary, in that a given factor can act as either a motiv-
ator or deterrent to uptake and use depending on the in-
dividual context. Our analysis led us to identify seven
third-order constructs. Figure 3 illustrates how the third
order constructs tend to be situated in terms of primacy
to the decision making process to take up and use HIV
prevention products, and how they can influence each
other in this process.
In this manner, the centrality of “Sexual Satisfaction”,
“Trust” and “Empowerment & Control” are emphasised
among those constructs that appear more proximal or
those that are functional or pragmatic, but which still
play a role in product uptake and use. The inter-
relationality of these constructs, illustrated by the over-
lapping circles in the centre of the framework which also
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connect with the other shapes in Fig. 3, is as important
as the individual constructs themselves, as no one
construct can be isolated and addressed without
acknowledging the others. In the remainder of this sec-
tion we use this framework as the basis for discussing
the broader context of the constructs, their meaning and
potential impact for policy and programming.
Core influencing constructs
Improved sexual satisfaction emerged as one of the
strongest motivators for using a particular product,
especially in relation to vaginal microbicides and the
diaphragm. However, this construct was typically
positioned within a partnership where trust and
empowerment mediated (or were mediated by)
enhanced sexual pleasure. Several authors highlighted
how the mere fact that sexual satisfaction for both part-
ners plays such a key role in broader relationship satis-
faction, and that in many respects vaginal microbicides
or diaphragm use help to enhance sexual pleasure,
means that this dimension of the product is central to
their uptake and use [29, 32].
Improved sexual satisfaction in a relationship can
directly lead to improved security between a couple,
where a husband may stop seeing other women and the
main partnership therefore becomes strengthened [32].
Product attributes themselves can also contribute to
trust, or lack thereof, in a given product. For instance,
the added wetness from a microbicide gel could denote
infidelity in the eyes of a male partner [28, 36], especially
in contexts where traditional preferences derived from
social norms are for dryer sex. This connotation of lack
of fidelity generates a lack of trust and ultimately demo-
tivated use of the product.
We found that many authors approached their research
from the perspective of empowerment, or control over
prevention choices. Women across the research expressed
how having something that was theirs and/or their choice
was important and empowering, but it was not necessarily
the primary motivation for use. This is significant to note
in the context of a global PrEP and vaginal microbicides
discourse that often emphasises empowerment of women
as a key component of such products [48–50]. While this
review demonstrates that empowerment and control is-
sues still play an important role in the decision to use a
new technology, they do not necessarily feature as the
primary factor in women’s’ thinking and must be
considered within individual contexts.
Empowerment could actually be diminished if a part-
ner discovered covert use of a product and became
angry or violent, and fear of these reactions led women
either to openly disclose or discuss use with a partner, or
stop use altogether. Some women found that empowerment
through building trust with their partner and strengthening
the relationship through open communication was a
positive by-product of introducing new prevention
options into the mix.
Proximal influencing constructs
Product use in the social-cultural environment consists
of multiple factors pertaining to interactions between
women and their communities, and the social norms
generated around traditional practices and beliefs, de-
noting women’s sense of ‘social well-being’.
Our analysis revealed the importance to women of
meeting both cultural norms and expectations of va-
ginal dryness [31] as well as vaginal cleansing [32].
This is where women carefully consider how vaginal
microbicide use might impact on good health and the
“vaginal environment” [32], which directly relates to
perceptions of well-being in the social-cultural envir-
onment as well as sexual satisfaction within the rela-
tionship. Several authors suggest that in countries or
areas where intravaginal insertion prior to sex (e.g. to
tighten or dry the vagina) is commonplace, accept-
ability of vaginal microbicides – and, therefore,
uptake and use – may be higher than in areas where
such practices are less common [28, 32].
The construct of personal well-being speaks to the
feelings women had about the impact of products on
their health more broadly. Use of products meant not
only a continuous process of engagement with health-
care services, but also a general sense of health and
cleanliness. A further key dimension of this construct
was how others might see women as ‘healthy’ by virtue
of their on-going healthcare engagement. This observa-
tion actually sits in contrast with other findings
described in some results that suggest women may be
the victims of stigma or discrimination if others come to
believe they are accessing HIV services because they are
sick, conflating services for prevention with those for
(HIV positive) treatment.
Functional & pragmatic influencing constructs
Inherent to the construct of efficacy and risk reduction
is the process of decision-making. Women will engage
in balancing the potential risk of HIV with the risk to
trust her partner, or the risk to intimacy within a
partnership that could be threatened by use of HIV pre-
vention products. Products that pose added benefits
from product attributes, such as clean lubrication from
the female condom or microbicide gel, could outweigh
potential issues around distrust or scepticism around
product use.
Several authors stressed that the efficacy of the
technology in preventing the transmission of HIV was
absolutely central to its perceived acceptability [28, 29,
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32], as well as its uptake and use. However, we found
that sometimes beliefs about a certain product was as,
or more powerful than the reality. For example, the
belief that a product could prevent more than HIV, that
it could ‘cleanse the blood’ or prevent other diseases
because of how it made the person feel when using or
taking it, was a strong motivation for use. Similarly, be-
lief that a product was extremely efficacious as a result
of experiencing side effects or a feeling of empowerment
promoted continued use.
In order to make effective use of the products women
need to be able to store, be able to confidently use, and
have barrier-free access to healthcare services. Products
must also be developed or formulated in such a way as
to be acceptable to women wanting to use them in the
medium or longer term. Vaginal microbicides and the
diaphragm, in particular, can be difficult for women to
insert in adequate time prior to sex and concern was
also expressed that their use may interfere with
traditional vaginal hygiene practices.
Further reflections on these findings
Since the time that this review was conducted, additional
qualitative evidence on perceptions of female-initiated
and controlled HIV prevention products or interven-
tions has emerged, particularly from trial research
around oral PrEP.. The HPTN/ADAPT study [51], which
compared daily to intermittent dosing of oral PrEP in a
phase II clinical trial setting, has recently published
qualitative research which further supports and develops
the findings in this paper. In this study, they found
nuanced motivations and barriers linked to perceptions
of safety taking PrEP, trust in what PrEP really was and
whether it really worked, whether its providers were
worthy of trust, and a sense of community commitment
and dedication with regards to adopting (or not) the
PrEP intervention. The insights related to trust, or lack
thereof, in oral PrEP have been further supported by
findings from the VOICE D study (a sub-study of the
main VOICE study on preferences and adherence) where
women expressed concerns around safety and efficacy of
PrEP as well as similar community perceptions which
affected their own thinking [52, 53]. As more data
continue to emerge from ongoing trial research as well
as the early PrEP implementation studies which will start
to publish results, perceptions which might create
product-specific stigma, distrust, and aversion will be
important to consider when designing messaging and
education campaigns. Additionally, it will be important
to ‘arm’ health workers and clinicians providing PrEP
will accurate information and careful training to be able
to address rumours head on.
In this review, oral PrEP was discussed less than other
products (such as microbicide gels or the ring) with
regard to sexual satisfaction, largely because it lacked
tangible attributes that could contribute to improved
pleasure. However, social marketing campaigns have
evolved since this review was conducted that capitalize
on the ability of PrEP to remove some of the fear around
sex which can then lead to improve satisfaction or pleas-
ure [54]. PrEP and other HIV prevention products may
present a new opportunity to develop discourse around
sexual pleasure even in places traditionally closed to
these notions.
Vaginal practices played a key role in much of the
research surrounding vaginal products such as the gel
and the ring with regards to traditions and habits of
women. Interestingly, the notion of “dry sex” was
revealed in some of the literature to be less about having
a dry vaginal environment, but rather more about the
cleanliness of the vagina and “hotness” of the sex. Regu-
lar clinic visits allowed women to be more consistently
free of STIs, and use of the gel provided clean lubrica-
tion, which most women and their male partners
enjoyed. If there is to be continued pursuit of vaginal
HIV prevention products, this line of enquiry may bene-
fit from further investigation.
Adherence, or the burden of adhering to a specific
HIV prevention product regimen, was not a theme that
emerged as prominently as others in this review. How-
ever more evidence has emerged recently about levels of
adherence required to ensure efficacy, and findings from
qualitative research may help to shed light on where
issues lie in maintaining consistent use. Oral PrEP in
particular requires high levels of adherence to confer
adequate protection, particularly among women [55, 56].
This will also be an important consideration for large-
scale PrEP implementation as well as for development of
new HIV prevention products.
Finally, as the research included in this review comes
from studies where participants received some form of
financial reimbursement for participation, and the
products were provided free of charge, it is not possible
to determine how perceptions of use may differ in a
context where this was not the case. Future research
could examine this further, and potentially use the
findings from this paper to develop surveys to also quan-
titatively assess motivations and barriers to use in more
‘real-world’ settings.
Strengths & Limitations
This is the first review paper of its kind to aggregate data
from across a large population of women, from multiple
sub-Saharan African countries, relating to a range of
female controlled HIV prevention products. In doing so
we have documented the key themes or issues that can
influence their uptake and use and how these overlap
according to context and the specific technology. The
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systematic review involved searches in all languages,
double screening and double extraction of relevant data
from each paper. Our explicit focus on studies where
the product of interest was available, rather than simply
the object of theoretical discussion with women, helps to
ensure the findings are grounded in personal experience.
The papers in this review, however, included mostly
data gathered in the context of clinical trials where
products were freely given and participants were usually
reimbursed for costs associated with participation (such
as transport to and from clinics). The unique environ-
ment and provision of wrap-around counselling and
treatment services does not often mirror the real-world
implementation of new products. Nevertheless, regard-
less of this, the themes that emerged were common
across a wide range of countries, implementation
contexts (including clinical trial and implementation
studies), and cultural settings, as well as across the
products themselves, suggesting a relatively robust body
of evidence. One crucial consideration, however, relates
to the construct of product use in the social cultural-
environment, where social norms are seen to influence
uptake and use of products. As those products found to
be efficacious are rolled out into countries and commu-
nities, the extent to which their use is ‘normative’ will
also change. This would certainly have affected the data
included in this review as none of the products had been
in the field long enough for use to have been normal-
ized. It is also important to note that while this review
of evidence only included perspectives from women, it is
clear that the perspectives of men influence women’s
choices, decision making, and effective use.
A further limitation of this analysis is the limited
nature of published qualitative research. Often it is
required, for word length purposes, to condense detailed
findings to a few sentences that capture their essence.
Understandably, the papers included in this review will
have focused on certain viewpoints, whereas there may
be many more data providing additional nuance, which
could contribute valuable insight.
Finally, while it is a strength of this review that we
have synthesized qualitative data from across research
contexts, it is also somewhat of a limitation that the
contexts were not more diverse and include more pure
implementation research studies. The body of evidence
for understanding the motivations and barriers to uptake
and use of female-initiated HIV prevention products can
be further strengthened by more lessons learned and
documented from the field.
Conclusions
This is an exciting time in HIV prevention as new
biomedical products are developed and systems put in
place to ensure their effective rollout. Health systems,
structural and direct contact level interventions relating
to new products need to take into account more than
just superficial notions of acceptability. Instead, they
should focus on a holistic approach including: aspects of
how a product can protect a partnership (in terms of
physical and emotional health); an awareness of the
significance of sexual satisfaction and enjoyment; an
understanding of the social and cultural norms influen-
cing product use; and include efforts to tackle the
continuing stigma associated with HIV. Structural and
individual level interventions aiming to improve uptake
and use of those products already available have tended
to focus on practical issues (e.g. access to products and
services, ability to use and store products safely, access
to hygienic facilities). These may be perceived as the
‘low hanging fruit’ as issues that lend themselves to
immediate intervention, but they do not necessarily re-
flect those concerns that are most central to effective
uptake and sustained use of the product from the
perspective of the user. While the reduction of transmis-
sion risk is essential for the use of any of these products,
and has justifiably been the focus of international
scientific attention, this is not often the key determining
feature of use. Formative research conducted in each
setting prior to the roll out of new product-based
interventions will help to ensure that communications
and educational materials are aligned to the local
cultural and social norms, and take account of both
personal concerns and personal values in safer, and
enjoyable, sexual practice.
Endnotes
1Microbicide gel can also be referred to in the literature
as topical PrEP, however, in this review we have kept is as
microbicide gel, or just gel.
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